Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Cytek BioSciences Inc’s stock clocked out at $6.20, down -1.12% from its previous closing price of $6.27. In other words, the price has decreased by -$1.12 from its previous closing price. On the day, 0.79 million shares were traded. CTKB stock price reached its highest trading level at $6.55 during the session, while it also had its lowest trading level at $6.07.
Ratios:
To gain a deeper understanding of CTKB’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 487.31. For the most recent quarter (mrq), Quick Ratio is recorded 6.01 and its Current Ratio is at 6.99. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 19 ’24 when Yan Ming sold 20,000 shares for $5.87 per share. The transaction valued at 117,400 led to the insider holds 5,988,502 shares of the business.
Yan Ming sold 1,900 shares of CTKB for $13,304 on Apr 09 ’24. The CHIEF TECHNOLOGY OFFICER now owns 6,008,502 shares after completing the transaction at $7.00 per share. On Mar 19 ’24, another insider, Yan Ming, who serves as the CHIEF TECHNOLOGY OFFICER of the company, sold 20,000 shares for $6.71 each. As a result, the insider received 134,200 and left with 6,010,402 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 813836800 and an Enterprise Value of 563051712. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.05 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 2.804 whereas that against EBITDA is -30.671.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.39, which has changed by -0.2278325 over the last 52 weeks, in comparison to a change of 0.25590587 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $11.70, while it has fallen to a 52-week low of $3.80. The 50-Day Moving Average of the stock is -6.32%, while the 200-Day Moving Average is calculated to be -12.99%.
Shares Statistics:
It appears that CTKB traded 714.93K shares on average per day over the past three months and 601040 shares per day over the past ten days. A total of 130.71M shares are outstanding, with a floating share count of 119.19M. Insiders hold about 9.20% of the company’s shares, while institutions hold 59.84% stake in the company. Shares short for CTKB as of 1713139200 were 7471493 with a Short Ratio of 10.45, compared to 1710460800 on 8506796. Therefore, it implies a Short% of Shares Outstanding of 7471493 and a Short% of Float of 7.290000000000001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Cytek BioSciences Inc (CTKB).On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.07, while EPS last year was -$0.05. The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.0 and -$0.1 for the fiscal current year, implying an average EPS of -$0.04. EPS for the following year is $0.1, with 6.0 analysts recommending between $0.21 and -$0.02.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $44.86M. It ranges from a high estimate of $46.18M to a low estimate of $41.59M. As of the current estimate, Cytek BioSciences Inc’s year-ago sales were $37.09MFor the next quarter, 5 analysts are estimating revenue of $49.34M. There is a high estimate of $50.9M for the next quarter, whereas the lowest estimate is $47.54M.
A total of 6 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $205.2M, resulting in an average revenue estimate of $207.95M. In the same quarter a year ago, actual revenue was $193.01MBased on 6 analysts’ estimates, the company’s revenue will be $247.17M in the next fiscal year. The high estimate is $266.8M and the low estimate is $224.85M.
